4//SEC Filing
Nassif David W. 4
Accession 0001636050-19-000085
CIK 0001636050other
Filed
Sep 23, 8:00 PM ET
Accepted
Sep 24, 5:15 PM ET
Size
5.8 KB
Accession
0001636050-19-000085
Insider Transaction Report
Form 4
Nassif David W.
Principal Financial Officer
Transactions
- Award
Restricted Stock Units
2019-09-21+30,120→ 30,120 total→ Common Shares (30,120 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
- [F2]50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.
Documents
Issuer
Axovant Gene Therapies Ltd.
CIK 0001636050
Entity typeother
Related Parties
1- filerCIK 0001636975
Filing Metadata
- Form type
- 4
- Filed
- Sep 23, 8:00 PM ET
- Accepted
- Sep 24, 5:15 PM ET
- Size
- 5.8 KB